Prihlásiť sa Zaregistrujte sa zadarmo

Výnosy Q/Q spoločnosti Financière de Tubize SA

Aká je hodnota metriky Výnosy Q/Q spoločnosti Financière de Tubize SA?

Hodnota metriky Výnosy Q/Q spoločnosti Financière de Tubize SA je -100.00%

Aká je definícia metriky Výnosy Q/Q?

Štvrťročný rast výnosov (Revenue Q/Q) z roku na rok je zvýšenie príjmov firmy v porovnaní s výsledkami v korešpondujúcom štvrťroku minulého roku a vyjadreného v percentách.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Výnosy Q/Q spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Financière de Tubize SA

Čomu sa venuje spoločnosť Financière de Tubize SA?

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.

Firmy s metrikou výnosy q/q podobnou spoločnosti Financière de Tubize SA